AB Science Postpones 2025 Half-Year Financial Report Publication to October

AB Science, a France-based biopharmaceutical company, has announced a minor delay regarding the release of its financial report for the first half of 2025. The company stated that the report will be published no later than Friday, October 10, 2025.

No specific reasons for the postponement were detailed in the announcement made on September 30, 2025. This adjustment to the previously anticipated schedule may draw attention from its investors and the financial community.

The company's core activities involve the development of new therapeutic solutions for both human and veterinary medicine. Key drug candidates in its pipeline include masitinib, currently being studied for neurodegenerative and inflammatory diseases, and AB8939.

Investors and market analysts will likely be monitoring the upcoming report closely for financial performance indicators and updates on the company's ongoing clinical development programs.